Division of Nephrology, Department of Medicine, Stanford University School of Medicine, Palo Alto, California, USA.
Clin J Am Soc Nephrol. 2011 Jul;6(7):1794-801. doi: 10.2215/CJN.01190211.
Treatment of anemia in patients with chronic kidney disease is a topic of increasing interest and controversy. However, anemia in the kidney transplant recipient has received relatively little attention in the literature despite the reported high prevalence of 30% to 40%. The pathogenesis of anemia among kidney transplant recipients is usually multifactorial, including compromised graft function, iron deficiency, immunosuppressive and other medications, and an inflammatory state causing erythropoietin resistance. It is unclear whether posttransplantation anemia is causally linked to cardiovascular events and mortality. Clinicians should screen kidney transplant recipients for posttransplantation anemia and carefully weigh the potential risks and benefits of treatment on an individual basis until well-designed, prospective studies provide further insight. This article reviews the prevalence, pathogenesis, and management of anemia in kidney transplant recipients.
治疗慢性肾脏病患者的贫血是一个日益受到关注和争议的话题。然而，尽管报道的患病率为 30%至 40%，但肾移植受者的贫血在文献中相对较少受到关注。肾移植受者贫血的发病机制通常是多因素的，包括移植物功能受损、缺铁、免疫抑制和其他药物以及导致促红细胞生成素抵抗的炎症状态。尚不清楚移植后贫血是否与心血管事件和死亡有因果关系。临床医生应筛查肾移植受者的移植后贫血，并在个体基础上仔细权衡治疗的潜在风险和益处，直到设计良好的前瞻性研究提供进一步的见解。本文综述了肾移植受者贫血的患病率、发病机制和治疗。
